Novo Nordisk A/S (NYSE:NVO) Trading Down 8.2% – Time to Sell?

Novo Nordisk A/S (NYSE:NVO)’s share price traded down 8.2% during mid-day trading on Thursday . The stock traded as low as $43.24 and last traded at $43.3150. 53,396,661 shares were traded during trading, an increase of 102% from the average session volume of 26,444,670 shares. The stock had previously closed at $47.19.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a 2026 share‑repurchase programme (up to DKK 15bn total; new tranche up to DKK 3.8bn) — a buyback that can support the share price and offset some investor concern. Novo repurchase programme
• Positive Sentiment: Novo declared a cash dividend (DKK 1.2751 per share payment scheduled for April) — another shareholder return that cushions downside.
• Neutral Sentiment: Company disclosure: trading by board members, executives and associated persons was reported today (routine compliance item; signals insiders are transacting but not necessarily directional). Insider trading disclosure
• Neutral Sentiment: Novo confirmed a planned U.S. launch of an oral Ozempic (oral semaglutide) in Q2 — potential longer‑term revenue diversification but unclear near‑term margin impact. Ozempic pill launch
• Negative Sentiment: Hims & Hers began offering a compounded, oral copy of Wegovy at an introductory $49 per month — a dramatic undercut to branded pricing that amplifies concerns about durable pricing power for GLP‑1 drugs and triggered today’s selling pressure. Hims & Hers launches $49 Wegovy copy
• Negative Sentiment: Novo said it will pursue legal action against Hims & Hers over mass compounding of Wegovy — a sign of escalating industry conflict that could lead to costly litigation and uncertainty over market access. Novo legal action vs Hims & Hers
• Negative Sentiment: Management already warned investors of a 2026 revenue and operating‑profit decline (guidance cited U.S. price cuts, margin pressure and competition) — that guidance drove a large multi‑day selloff and remains the primary framework for today’s weakness. Shock 2026 guidance
• Negative Sentiment: Regional weakness: Ozempic sales in greater China fell last year — an early sign that growth is softening outside the U.S. as competition intensifies. Ozempic China sales drop

Analyst Ratings Changes

Several research analysts have weighed in on the company. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday. Citigroup began coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating for the company. The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. CICC Research initiated coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target for the company. Finally, HSBC reaffirmed a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Stock Performance

The stock has a market cap of $193.40 billion, a PE ratio of 12.59 and a beta of 0.67. The stock has a fifty day simple moving average of $53.75 and a two-hundred day simple moving average of $54.13. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 23.84%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lockheed Martin Investment Management Co. boosted its holdings in shares of Novo Nordisk A/S by 179.4% in the 2nd quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock valued at $2,999,000 after buying an additional 27,900 shares during the last quarter. Martin Capital Partners LLC increased its holdings in Novo Nordisk A/S by 53.8% during the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after buying an additional 41,129 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. bought a new stake in Novo Nordisk A/S during the third quarter worth $1,294,000. Guild Investment Management Inc. lifted its stake in Novo Nordisk A/S by 20.7% in the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock valued at $2,553,000 after acquiring an additional 6,345 shares during the last quarter. Finally, Markel Group Inc. lifted its stake in Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after acquiring an additional 110,061 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.